Agenus Inc.

NasdaqCM:AGEN 주식 보고서

시가총액: US$319.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Agenus 관리

관리 기준 확인 2/4

Agenus' CEO는 Garo Armen, Jan1994 에 임명되었습니다 의 임기는 30.42 년입니다. 총 연간 보상은 $ 5.86M, 12.1% 로 구성됩니다. 12.1% 급여 및 87.9% 보너스(회사 주식 및 옵션 포함). 는 $ 1.74M 가치에 해당하는 회사 주식의 0.64% 직접 소유합니다. 1.74M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3.7 년입니다.

주요 정보

Garo Armen

최고 경영자

US$5.9m

총 보상

CEO 급여 비율12.1%
CEO 임기30.4yrs
CEO 소유권0.6%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간3.7yrs

최근 관리 업데이트

Recent updates

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22
Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09
News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04
A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10
Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Oct 12

Agenus New Trials Set It Up For The Long Haul

Sep 27

Agenus: It's Always Tomorrow

Sep 16

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Aug 09

Agenus: Successfully Pulled Itself Away From Disaster

Jul 04

Agenus: Not Quite Enough

Apr 19

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Mar 06
Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Agenus: Making Another Effort With The FDA

Jan 25

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11
Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

FDA accepts Agenus' balstilimab BLA under "priority review" status

Jun 17

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

May 26

CEO 보상 분석

Garo Armen 의 보수는 Agenus 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$6mUS$710k

-US$246m

Sep 30 2023n/an/a

-US$271m

Jun 30 2023n/an/a

-US$263m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$6mUS$689k

-US$220m

Sep 30 2022n/an/a

-US$215m

Jun 30 2022n/an/a

US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$10mUS$655k

-US$24m

Sep 30 2021n/an/a

US$4m

Jun 30 2021n/an/a

-US$226m

Mar 31 2021n/an/a

-US$190m

Dec 31 2020US$6mUS$677k

-US$181m

Sep 30 2020n/an/a

-US$174m

Jun 30 2020n/an/a

-US$168m

Mar 31 2020n/an/a

-US$171m

Dec 31 2019US$10mUS$634k

-US$108m

Sep 30 2019n/an/a

-US$126m

Jun 30 2019n/an/a

-US$113m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$3mUS$610k

-US$160m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$151m

Mar 31 2018n/an/a

-US$158m

Dec 31 2017US$4mUS$593k

-US$121m

보상 대 시장: Garo 의 총 보상 ($USD 5.86M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Garo 의 보상이 증가했습니다.

CEO

Garo Armen (71 yo)

30.4yrs

테뉴어

US$5,856,319

보상

Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...

리더십 팀

이름위치테뉴어보상소유권
Garo Armen
Founder30.4yrsUS$5.86m0.64%
$ 2.1m
Christine Klaskin
VP of Finance17.7yrsUS$712.75k0.037%
$ 117.2k
Steven O'Day
Chief Medical Officer3.4yrsUS$1.44m0.065%
$ 207.4k
Craig Winter
Chief Information Officer2.4yrs데이터 없음데이터 없음
Zack Armen
Head of Investor Relationsno data데이터 없음데이터 없음
Tracy Clemente
Chief People Officer2.4yrs데이터 없음데이터 없음
Alfred Dadson
Chief Manufacturing Officerno data데이터 없음데이터 없음
Eric Humes
Chief Quality Officer2.4yrs데이터 없음데이터 없음
Todd Yancey
Member of Advisory Board & Chief Strategic Advisorless than a year데이터 없음데이터 없음
Robin Taylor
Chief Commercial Officerless than a year데이터 없음데이터 없음
Nils Eckardt
Chief Medical Affairs Officerless than a year데이터 없음데이터 없음
Jennifer Buell
Director and President & CEO of MiNK Therapeutics2.4yrsUS$7.42m0.065%
$ 208.2k

2.4yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 관리: AGEN 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Garo Armen
Founder25.4yrsUS$5.86m0.64%
$ 2.1m
Todd Yancey
Member of Advisory Board & Chief Strategic Advisor1.4yrs데이터 없음데이터 없음
Jennifer Buell
Director and President & CEO of MiNK Therapeuticsno dataUS$7.42m0.065%
$ 208.2k
Robert Stein
Member of Advisory Board1.4yrsUS$1.04m데이터 없음
Ulf Wiinberg
Independent Director8.1yrsUS$366.39k0.030%
$ 94.5k
Timothy Wright
Independent Lead Director17.5yrsUS$385.50k0.013%
$ 42.2k
Larry Norton
Member of Advisory Board1.4yrs데이터 없음데이터 없음
Brian Corvese
Independent Director17.3yrsUS$888.14k0.022%
$ 70.1k
Susan Hirsch
Independent Director3.7yrsUS$242.00k0.028%
$ 90.4k

3.7yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: AGEN 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.